DK2321343T3 - New retinoidinducerbar factor and uses thereof - Google Patents
New retinoidinducerbar factor and uses thereof Download PDFInfo
- Publication number
- DK2321343T3 DK2321343T3 DK09762718.6T DK09762718T DK2321343T3 DK 2321343 T3 DK2321343 T3 DK 2321343T3 DK 09762718 T DK09762718 T DK 09762718T DK 2321343 T3 DK2321343 T3 DK 2321343T3
- Authority
- DK
- Denmark
- Prior art keywords
- rinf
- cells
- expression
- atra
- cell
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 claims description 100
- 108090000623 proteins and genes Proteins 0.000 claims description 90
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 23
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 21
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 201000010893 malignant breast melanoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 141
- 101000947154 Homo sapiens CXXC-type zinc finger protein 5 Proteins 0.000 description 126
- 102100036167 CXXC-type zinc finger protein 5 Human genes 0.000 description 125
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 73
- 229930002330 retinoic acid Natural products 0.000 description 71
- 108091027967 Small hairpin RNA Proteins 0.000 description 39
- 239000004055 small Interfering RNA Substances 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 108020004999 messenger RNA Proteins 0.000 description 36
- 230000004069 differentiation Effects 0.000 description 29
- 238000011282 treatment Methods 0.000 description 28
- 238000002493 microarray Methods 0.000 description 23
- 101150082557 CXXC5 gene Proteins 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 239000013598 vector Substances 0.000 description 18
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 17
- 150000004492 retinoid derivatives Chemical class 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 230000006698 induction Effects 0.000 description 15
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 14
- 230000011712 cell development Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 13
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 229960001727 tretinoin Drugs 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 230000035800 maturation Effects 0.000 description 11
- 210000000066 myeloid cell Anatomy 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003197 gene knockdown Methods 0.000 description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000011132 hemopoiesis Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 102000000646 Interleukin-3 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 208000014951 hematologic disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940076264 interleukin-3 Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 108090000064 retinoic acid receptors Proteins 0.000 description 4
- 102000003702 retinoic acid receptors Human genes 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 230000001173 tumoral effect Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003887 myelocyte Anatomy 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 101100305156 Brugia malayi rpp-2 gene Proteins 0.000 description 2
- 102100036168 CXXC-type zinc finger protein 1 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 description 2
- 101000947157 Homo sapiens CXXC-type zinc finger protein 1 Proteins 0.000 description 2
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 description 2
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 description 2
- 101000581507 Homo sapiens Methyl-CpG-binding domain protein 1 Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100027383 Methyl-CpG-binding domain protein 1 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101150084935 PTER gene Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000002071 myeloproliferative effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000004765 promyelocyte Anatomy 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000027483 retinoid hormone receptors Human genes 0.000 description 2
- 108091008679 retinoid hormone receptors Proteins 0.000 description 2
- 101150110619 rpp-2 gene Proteins 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 238000009424 underpinning Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- 206010068532 5q minus syndrome Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102100035685 CXXC-type zinc finger protein 4 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 101000947152 Homo sapiens CXXC-type zinc finger protein 4 Proteins 0.000 description 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001095089 Homo sapiens PML-RARA-regulated adapter molecule 1 Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100037019 PML-RARA-regulated adapter molecule 1 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101150025079 RPS14 gene Proteins 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20082550 | 2008-06-09 | ||
| NO20090358A NO20090358L (no) | 2008-06-09 | 2009-01-23 | Retinoid-induserbar faktor, og anvendelse derav |
| PCT/NO2009/000214 WO2009151337A2 (en) | 2008-06-09 | 2009-06-09 | Novel retinoid inducible factor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2321343T3 true DK2321343T3 (en) | 2015-08-24 |
Family
ID=41328567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09762718.6T DK2321343T3 (en) | 2008-06-09 | 2009-06-09 | New retinoidinducerbar factor and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120003181A1 (enExample) |
| EP (1) | EP2321343B1 (enExample) |
| JP (1) | JP5797554B2 (enExample) |
| DK (1) | DK2321343T3 (enExample) |
| ES (1) | ES2542866T3 (enExample) |
| NO (2) | NO20090358L (enExample) |
| WO (1) | WO2009151337A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2616540T3 (es) | 2010-07-21 | 2017-06-13 | Bergen Teknologioverføring As | Métodos para determinar un pronóstico de supervivencia para un paciente con leucemia |
| KR101721028B1 (ko) * | 2014-02-12 | 2017-03-29 | 연세대학교 산학협력단 | 상처 치유 촉진용 조성물 |
| WO2024074713A1 (en) * | 2022-10-07 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Method to generate improving car-t cells |
| CN116004829A (zh) * | 2023-01-04 | 2023-04-25 | 上海良福生物科技有限公司 | 一种notch1的胞内活化结构域（nicd1）调节剂及其应用 |
| CN119060944B (zh) * | 2023-05-31 | 2025-11-11 | 士泽生物医药（苏州）有限公司 | 利用粒细胞集落刺激因子诱导心肌细胞分化成熟的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6906800A (en) * | 1999-08-17 | 2001-03-13 | Incyte Genomics, Inc. | Membrane associated proteins |
| CA2625403A1 (en) * | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
-
2009
- 2009-01-23 NO NO20090358A patent/NO20090358L/no not_active Application Discontinuation
- 2009-06-09 DK DK09762718.6T patent/DK2321343T3/en active
- 2009-06-09 JP JP2011513442A patent/JP5797554B2/ja not_active Expired - Fee Related
- 2009-06-09 WO PCT/NO2009/000214 patent/WO2009151337A2/en not_active Ceased
- 2009-06-09 EP EP09762718.6A patent/EP2321343B1/en not_active Not-in-force
- 2009-06-09 US US12/997,034 patent/US20120003181A1/en not_active Abandoned
- 2009-06-09 ES ES09762718.6T patent/ES2542866T3/es active Active
-
2010
- 2010-06-04 NO NO20100815A patent/NO20100815A1/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009151337A3 (en) | 2010-07-08 |
| EP2321343B1 (en) | 2015-06-03 |
| WO2009151337A2 (en) | 2009-12-17 |
| NO20090358L (no) | 2009-12-10 |
| NO20100815A1 (no) | 2011-03-09 |
| ES2542866T3 (es) | 2015-08-12 |
| EP2321343A2 (en) | 2011-05-18 |
| US20120003181A1 (en) | 2012-01-05 |
| JP2011525352A (ja) | 2011-09-22 |
| JP5797554B2 (ja) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Atanackovic et al. | Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells | |
| Espinosa et al. | The Sjogren’s syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death | |
| Pendino et al. | Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis | |
| US20160282354A1 (en) | Compositions and methods for selecting a treatment for b-cell neoplasias | |
| Tian et al. | LncRNA AK036396 inhibits maturation and accelerates immunosuppression of polymorphonuclear myeloid–derived suppressor cells by enhancing the stability of ficolin B | |
| Ricci et al. | Role of the glucocorticoid‐induced leucine zipper gene in dexamethasone‐induced inhibition of mouse neutrophil migration via control of annexin A1 expression | |
| Chakraborty et al. | Stanniocalcin-1 regulates endothelial gene expression and modulates transendothelial migration of leukocytes | |
| EP3458473A1 (en) | Markers selectively deregulated in tumor-infiltrating regulatory t cells | |
| DK2321343T3 (en) | New retinoidinducerbar factor and uses thereof | |
| Humbert et al. | Deregulated expression of Kruppel-like factors in acute myeloid leukemia | |
| Dmitriev et al. | Dux4 controls migration of mesenchymal stem cells through the Cxcr4-Sdf1 axis | |
| Bondeva et al. | Advanced glycation end-products suppress neuropilin-1 expression in podocytes | |
| Rizzi et al. | The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells | |
| Xiong et al. | Glutamylation of deubiquitinase BAP1 controls self-renewal of hematopoietic stem cells and hematopoiesis | |
| US8795650B2 (en) | Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells | |
| Jiang et al. | Hemgn is a direct transcriptional target of HOXB4 and induces expansion of murine myeloid progenitor cells | |
| Le et al. | Characterization of the ETO and AML1–ETO proteins involved in the 8; 21 translocation in acute myelogenous leukemia | |
| Ramsey et al. | The zinc finger transcription factor ZXDC activates CCL2 gene expression by opposing BCL6-mediated repression | |
| Nagato et al. | Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy | |
| US20190209618A1 (en) | Methods and compositions for expansion of hematopoietic stem and/or progenitor cells employing a cytochrome p450 1b1 (cyp1b1) inhibitor or a musashi-2 (msi2) activator | |
| CN115595361B (zh) | Znf683作为免疫抑制靶点在诱导t细胞免疫耐受调控中的应用 | |
| US20250381241A1 (en) | Methods and compositions to modulate riok2 | |
| US20140235481A1 (en) | Cancer biomarker and methods of use thereof | |
| Im | Targeting O-GlcNAc transferase (OGT) as a novel therapeutic strategy for EVI1+ acute myeloid leukemia: enhancing mitochondrial priming for improved outcomes | |
| WO2023097119A2 (en) | Methods and compositions to modulate riok2 |